Ana Beatris Rossi

19PUBLICATIONS
70CO-AUTHORS
Major global burdens of diseaseSocial epidemiologyPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jan 31, 2026
Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials.

Andreas Wollenberg, Eric L Simpson, Yael A Leshem

|Oct 04, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema Questionnaire.

Eric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin

|Sep 24, 2025
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults.

Richard G Langley, Guy Gherardi, Anna Coleman

|Jul 11, 2025
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.

Sonja Ständer, Andreas Pinter, Firas G Hougeir

|Feb 17, 2024
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.

Mike Bastian, Nick Freemantle, Ana B Rossi

|Apr 30, 2023
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.

Carsten Flohr, Alan D Irvine, Michael J Cork

Pageof 4

Frequent Collaborators

5 joint publications

Brad Shumel

4 joint publications

Andreas Wollenberg

3 joint publications

Jonathan I Silverberg

3 joint publications

Eric L Simpson